Cargando…

Pretest PSA and Restaging PSMA PET/CT Predict Survival in Biochemically Recurrent Prostate Cancer

Background: A biochemical recurrence (BCR) risk model was created based on pretest prostate specific antigen (PSA) and groupings by restaging prostate specific membrane antigen (PSMA) PET/CT. Methods: A cohort of 1216 BCR patients were analyzed for overall survival (OS) according to the PSA threshol...

Descripción completa

Detalles Bibliográficos
Autores principales:	von Eyben, Rie, Hoffmann, Manuela Andrea, Soydal, Cigdem, Virgolini, Irene, Tuncel, Murat, Gauthé, Mathieu, Kapp, Daniel S., von Eyben, Finn Edler
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10525266/ https://www.ncbi.nlm.nih.gov/pubmed/37760775 http://dx.doi.org/10.3390/biomedicines11092333

Ejemplares similares

A Risk Model for Patients with PSA-Only Recurrence (Biochemical Recurrence) Based on PSA and PSMA PET/CT: An Individual Patient Data Meta-Analysis
por: von Eyben, Rie, et al.
Publicado: (2022)

Correction: von Eyben et al. A Risk Model for Patients with PSA-Only Recurrence (Biochemical Recurrence) Based on PSA and PSMA PET/CT: An Individual Patient Data Meta-Analysis. Cancers 2022, 14, 5461
por: von Eyben, Rie, et al.
Publicado: (2023)

(68)Ga-PSMA PET/CT for Patients with PSA Relapse after Radical Prostatectomy or External Beam Radiotherapy
por: von Eyben, Finn Edler, et al.
Publicado: (2021)

Comparison of [(18)F]PSMA-1007 with [(68)Ga]Ga-PSMA-11 PET/CT in Restaging of Prostate Cancer Patients with PSA Relapse
por: Hoffmann, Manuela A., et al.
Publicado: (2022)

Optimizing PSMA Radioligand Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Meta-Analysis
por: von Eyben, Finn Edler, et al.
Publicado: (2020)

On the Way for Patients with Prostate Cancer to the Best Use of PSMA
por: von Eyben, Finn Edler, et al.
Publicado: (2022)

(177)Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer
por: von Eyben, Finn Edler, et al.
Publicado: (2019)

PSMA diagnostics and treatments of prostate cancer become mature
por: von Eyben, Finn Edler, et al.
Publicado: (2018)

Third-line treatment and (177)Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review
por: von Eyben, Finn Edler, et al.
Publicado: (2017)

Metastatic extent predicts survival as patients with metastatic castration-resistant prostate cancer are treated with (177)Lu-PSMA radioligand therapy
por: von Eyben, Finn Edler, et al.
Publicado: (2020)

(177)Lu-PSMA Radioligand Therapy Is Favorable as Third-Line Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
por: von Eyben, Finn E., et al.
Publicado: (2021)

Primary Staging of Prostate Cancer Patients with [(18)F]PSMA-1007 PET/CT Compared with [(68)Ga]Ga-PSMA-11 PET/CT
por: Hoffmann, Manuela A., et al.
Publicado: (2022)

(177)Lu-PSMA-617 radioligand therapy for a patient with lymph node metastatic prostate cancer
por: von Eyben, Finn E., et al.
Publicado: (2017)

Separate Chinese lines for prostate cancer?
por: von Eyben, Finn Edler
Publicado: (2019)

Meta-Analysis of Gene Expressions in Testicular Germ Cell Tumor Histologies
por: von Eyben, Finn Edler, et al.
Publicado: (2020)

Restaging the Biochemical Recurrence of Prostate Cancer with [(68)Ga]Ga-PSMA-11 PET/CT: Diagnostic Performance and Impact on Patient Disease Management
por: Fourquet, Aloÿse, et al.
Publicado: (2021)

Testicular germ cell tumors type 2 have high RNA expression of LDHB, the gene for lactate dehydrogenase subunit B
por: von Eyben, Finn Edler, et al.
Publicado: (2021)

(68)Ga-PSMA-11 PET/CT in restaging castration-resistant nonmetastatic prostate cancer: detection rate, impact on patients’ disease management and adequacy of impact
por: Fourquet, Aloÿse, et al.
Publicado: (2020)

PSA and PSA Kinetics Thresholds for the Presence of (68)Ga-PSMA-11 PET/CT-Detectable Lesions in Patients with Biochemical Recurrent Prostate Cancer
por: Hoffmann, Manuela Andrea, et al.
Publicado: (2020)

Epigenetic Regulation of Driver Genes in Testicular Tumorigenesis
por: von Eyben, Finn E., et al.
Publicado: (2023)

Dual-Time Point [(68)Ga]Ga-PSMA-11 PET/CT Hybrid Imaging for Staging and Restaging of Prostate Cancer
por: Hoffmann, Manuela A., et al.
Publicado: (2020)

Medical Scribe Impact on Provider Efficiency in Outpatient Radiation Oncology Clinics Before and During the COVID-19 Pandemic
por: Devine, Max, et al.
Publicado: (2022)

The positivity rate of 68Gallium-PSMA-11 ligand PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer
por: Hoffmann, Manuela A., et al.
Publicado: (2019)

Pilot study of combined FDG‐PET and dynamic contrast‐enhanced CT of locally advanced cervical carcinoma before and during concurrent chemoradiotherapy suggests association between changes in tumor blood volume and treatment response
por: Banks, Thomas I., et al.
Publicado: (2018)

Role of Early PET/CT Imaging with 68Ga-PSMA in Staging and Restaging of Prostate Cancer
por: Barakat, Andrew, et al.
Publicado: (2020)

F-18 PSMA Uptake in Male Breast Cancer during Restaging Evaluation of Carcinoma Prostate
por: Zade, Anand, et al.
Publicado: (2022)

Comparison of (68)Ga-PSMA PET/CT and (18)F-PSMA PET/CT of a Patient with Prostate Cancer Recurrence on Urinary Bladder Wall
por: Soydal, Çiğdem, et al.
Publicado: (2023)

Combined Intravenous Urogram and 68Ga-PSMA PET/ CT for Improved Staging and Restaging of Prostate Cancer
por: McBean, Rhiannon, et al.
Publicado: (2020)

Tumor immunologic heterogeneity influences response to radiation and combination immunotherapy
por: Aguilera, Todd, et al.
Publicado: (2015)

Alpha-foetoprotein and human chorionic gonadotropin in men with maldescended testes.
por: von Eyben, F., et al.
Publicado: (1980)

EAU Biochemical Recurrence Risk Classification and PSA Kinetics Have No Value for Patient Selection in PSMA-Radioguided Surgery (PSMA-RGS) for Oligorecurrent Prostate Cancer
por: Falkenbach, Fabian, et al.
Publicado: (2023)

Stereotactic body radiation therapy for adrenal gland metastases: Outcomes and toxicity
por: Toesca, Diego A.S., et al.
Publicado: (2018)

Reirradiation with stereotactic body radiation therapy after prior conventional fractionation radiation for locally recurrent pancreatic adenocarcinoma
por: Koong, Amanda J., et al.
Publicado: (2017)

Stereotactic Body Radiation Therapy for Cholangiocarcinoma: Optimizing Locoregional Control With Elective Nodal Irradiation
por: Kozak, Margaret M., et al.
Publicado: (2019)

Evaluation of transperineal ultrasound imaging as a potential solution for target tracking during hypofractionated radiotherapy for prostate cancer
por: Han, Bin, et al.
Publicado: (2018)

Recurrence risk factors in stage IA grade 1 endometrial cancer
por: Nwachukwu, Chika, et al.
Publicado: (2021)

High-resolution electrical and chemical characterization of nm-scale organic and inorganic devices
por: Eyben, Pierre
Publicado: (2013)

Multiplexed Single-Cell Measurements of FDG Uptake and Lactate Release Using Droplet Microfluidics
por: Sengupta, Debanti, et al.
Publicado: (2019)

Early PSA Change after [(177)Lu]PSMA-617 Radioligand Therapy as a Predicator of Biochemical Response and Overall Survival
por: Kind, Felix, et al.
Publicado: (2021)

Detection Efficacy of (68)Ga-PSMA-11 PET/CT in Biochemical Recurrence of Prostate Cancer with Very Low PSA Levels: A 7-Year, Two-Center “Real-World” Experience
por: Burgard, Caroline, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cm1n00gdf3mv8e8ptqfriaqpt0